ABCSG 42/PALLAS Summary

PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Start: 08/2015; national: 10/2015
Coordinating investigator: Gnant, Michael; Vienna
Sample size: 4.600 (international)
Design:
(Click to enlarge)
ABCSG 42/PALLAS

 

Link for studyteam-members only

Further information about this trial

Access to these informations only with keyword. If required, please ask the responsible project manager.